Inoculation of rabbits and mice with a vaccinia-rabies glycoprotein recombinant (V-RG) virus resulted in rapid induction of high concentrations of rabies virus-neutralizing antibodies and protection from severe intracerebral challenge with several strains of rabies virus. Protection from virus challenge also was achieved against the rabies-related Duvenhage virus but not against the Mokola virus. Effective immunization by V-RG depended on the expression of a rabies glycoprotein that registered proline rather than leucine as the eighth amino acid from its NH2 terminus (V-RGpro8). A minimum dose required for effective immunization of mice was 104 plaque-forming units of V-RGpro8 virus. fi-propiolactone-inactivated preparations of V-RGpro8 virus also induced high levels of rabies virus-neutralizing antibody and protected mice against intracerebral challenge with street rabies virus. VRGpro8 virus was highly effective in priming mice to generate a secondary rabies virus-specific cytotoxic T-lymphocyte response following culture of lymphocytes with either ERA or PM strains of rabies virus.
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Rabies is a disease of the central nervous system of major importance to human and veterinary medicine. The etiologic agent, rabies virus, is composed of five structural proteins and a linear, single-stranded RNA genome of negative sense. The rabies virus glycoprotein (G) forms surface projections through the viral lipid envelope and is the only protein capable of inducing and reacting with virus-neutralizing antibody (VNA) (1, 2) . Several studies have established that the isolated G is capable of protecting animals against rabies (for review, see ref. 3) .
Recently, cloned cDNA copies of the G mRNA from two rabies virus strains have been isolated and sequenced (4, 5) . Expression of either G in bacterial hosts has so far failed to yield a product capable of immunizing animals against rabies (5) (6) (7) . In order to provide post-translational modifications potentially necessary for production of authentic rabies virus G, a vector system allowing expression of rabies G in eukaryotic hosts was sought. To this end, successful expression, immunization, and protection has been reported with infectious vaccinia virus recombinants containing foreign genes such as hepatits B surface antigen, influenza virus hemagglutinin, and herpes simplex virus glycoprotein D (8) (9) (10) (11) (12) .
This study compares the biologic and protective properties of two vaccinia virus recombinants expressing ERA strain rabies G proteins differing at a single amino acid residue. We report that infection of cells with either vaccinia virus recombinant resulted in the expression of a novel rabies G; however, only one of these products induced virusneutralizing activity, cytotoxic T-cell memory, and protection against an intracerebral challenge with rabies virus.
MATERIALS AND METHODS Cells and Viruses. Monolayer cultures of BHK-21 clone 13 cells (13) and NA neuroblastoma cells of A/J mouse origin (14) were grown at 370C in Eagle's minimum essential medium supplemented with 10% fetal calf serum as described (15) . The ERA strain of rabies virus (16) (18) and Mokola strain IbAn 27377 (19) virus. A stock of each challenge virus was prepared from NA or BHK-21 cells and titrated by intracerebral inoculation into 5-to 6-wk-old ICR mice. Additional street rabies viruses used for testing the virus-neutralizing activity of antisera were isolated in 1983 from Eptesicusfuscus bat in Ontario, Canada, in 1974 from salivary glands of a red fox in France, and in 1956 from human brain in China (strain CTN-1) provided through the World Health Organization (Geneva); also used was rabies-related Lagos bat virus (19) . Wild-type vaccinia viruses (strains WR and Copenhagen) were prepared in tissue culture and purified from cytoplasmic extracts by sucrose gradient centrifugation (20) . Vaccinia recombinant viruses containing cloned rabies G cDNA were constructed by using methods previously described (21) (22) (23) . The vaccinia-rabies glycoprotein recombinant (V-RG) virus containing the coding sequence for proline as the eighth amino acid of the rabies virion G is designated V-RGpro8 (VVTGgRAB in ref. 23) , and that which codes for leucine as the eighth amino acid is designated V-RGleu8. Infectivity titers of wild-type vaccinia and V-RG recombinant viruses were determined by a plaque assay on CER cells as described for rabies virus (24 (29) . The virus neutralization titers for antibodies directed against vaccinia virus was determined by a plaque reduction assay with monolayers of CER cells (15) .
Detection of Antigen by Immunofluorescence. Rabies G in V-RG virus-infected cells was visualized by indirect immunofluorescence in live or acetone-fixed cells using anti-G antiserum as described elsewhere (29 for 5 days at 37TC in 5% C02/95% air, the cells were washed in Eagle's minimum essential medium with 2% fetal calf serum and titrated for cytotoxicity in a 6-hr 51Cr-release assay as described (30) . Infection of NA target cells with wild-type vaccinia or V-RGpro8 viruses was carried out as described for rabies virus (30) except that the infected cells were incubated in siliconized Petri dishes for 5-6 hr to allow expression of surface antigens. Cells were then labeled with 51Cr and used as targets. Results are presented as 30% lytic units (LU30) and take into account the spontaneous release of 51C1 iqto the medium (10-24%) and the maximum release in detergent. bne LU30 is defined as the number of effector cells required to achieve 30% specific 51Cr release. A large number of LU30 per culture indicates a potent CTL population.
RESULTS
Expression of Rabies G in Vaccinia Virus Vectors. The rabies-specific G cDNA isolated by Anilionis et al. (4) was inserted into the BamHI site of plasmid pGS20 so as to be controlled by an early vaccinia virus promoter translocated within the thymidine kinase gene (22) . The chimeric gene formed in this manner contains the vaccinia RNA start site juxtaposed with the rabies translational initiation codon so as to avoid the production of a fusion protein. This plasmid construct was used to transfect vaccinia virus (strain WR)-infected cells to prepare a recombinant virus that contained the rabies G cDNA inserted into the thymidine kinase locus (V-RGleu8). Successful expression of a novel rabies G in VRGleu8 virus-infected BHK-21 cells resulted in a protein that was metabolically labeled with [35S]methionine and [3H]glucosamine, was immunoprecipitable with polyclonal rabbit anti-G antibodies, but which migrated faster than rabies virion G in NaDodSO4/polyacrylamide gel. In VRGleu8 virus-infected BHK-21 cells, the pattern of immunofluorescence suggested that the protein expressed by VRGleu8 virus was not in a native configuration (Fig. 1) . First, the fluorescence that is characteristic of the rabies virus G on the surface of cells was weak in V-RGleu8 virus-infected cells, where the majority of antigen was detected within the cytoplasm ( Fig. 1 A and B) . Secondly, a panel of anti-G monoclonal antibodies that bind only to native rabies virus G failed to detect the V-RGleu8 virus-expressed antigen (not shown). Moreover, injection of V-RGleu8 virus into animals failed to induce rabies VNA (Table 1) and to protect against rabies.
Amino acid analysis of the NH2 terminus of the rabies virus G (32) revealed a discrepancy at amino acid position 8 (proline) with the predicted sequence (leucine) of the original cDNA clone (4). By sequencing this entire viral G gene, this amino acid change and one other at position 399 (leucine to valine) were identified (ref. 33 ; data not shown). Assuming that the change near the NH2 terminus might have a greater impact on the structure formation of nascent G, we modified the cDNA clone by site-directed mutagenesis to rectify the amino acid at position 8 (23) . In addition, the guanosine tail originally introduced for cloning the cDNA was removed since it may impede expression (23). This modified DNA was inserted into plasmid pTG186 (23) and subsequently transferred into vaccinia virus to generate the recombinant designated V-RGpro8. The Copenhagen strain of vaccinia virus used for human vaccination was used as the vector. Infection of BHK-21 cells by V-RGpro8 virus resulted in expression of a rabies G on the cell surface and in cytoplasm detected by immunofluorescence ( Fig. 1 C and D) . The protein expressed by this recombinant virus reacted with a panel of anti-G monoclonal antibodies in a pattern identical with native rabies virus G (23) . Induction of VNA and Protection Against Rabies. Inoculation of rabbits and mice with V-RGpro8 virus resulted in a rapid induction of rabies VNA (Table 1 ). In rabbits, rabies VNA titers at 5, 11, and 14 days after inoculation were 800, 10,000, and >30,000, respectively. Vaccinia VNA (Fig. 3 A and B) . These CTL were specific only for target cells expressing rabies G (i.e., infected with ERA rabies virus or with VRGpro8 virus). Target cells infected with V-RGpro8 virus were comparatively resistant to lysis, perhaps reflecting differences in density or display of rabies G. In contrast, lymphocytes from V-RGpro8-primed mice lysed only vaccinia or V-RGpro8 virus-infected cells after stimulation with inactivated, purified V-RGpro8 virus (Fig. 3C ). Spleen cells from mice primed with vaccinia virus generated no CTL activity after stimulation with rabies viruses. In another experiment, lymphocytes from mice primed with ERA rabies virus generated a strong secondary CTL response after culture with either inactivated PM or ERA rabies virus (Fig. 3 D and E) , whereas inactivated V-RGpro8 virus was ineffective at the dilutions tested (Fig. 3F ) despite evidence that this preparation contained rabies G (see below).
Immunogenicity of Inactivated V-RGpro8 Virus. The abili- Minimum protective dose of V-RGpro8 virus. Groups of 10 mice were inoculated in the footpad with serial 10-fold dilutions of V-RGpro8 virus. Levels of rabies VNA were determined 7 (o) and 14 (e) days after infection. On day 15, mice were challenged intracerebrally with 2400 mouse LD50 of MD5951 rabies virus (a).
ty of f3PL-inactivated preparations of V-RGpro8 virus to induce an anti-rabies immune response was tested. Extracts of V-RGpro8 virus-infected cells, purified V-RGpro8 virus, and G isolated from V-RGpro8 virus-infected cell extracts by using an affinity column prepared with anti-rabies virus G antibody, were inactivated and inoculated intraperitoneally into mice. The mice were inoculated again after 7 days and challenged intracerebrally with 240 LD50 of MD5951 rabies virus after a further 7 days. All three preparations induced high levels of rabies VNA and protected against rabies (Table 2 ).
DISCUSSION
The construction of vaccinia virus recombinants expressing genes derived from pathogenic agents has great potential for the production of vaccines. In this report we demonstrate the effectiveness of live and inactivated experimental rabies vaccines prepared by this technology. Initially, we constructed a WR strain vaccinia recombinant virus incorporating the ERA rabies virus G cDNA sequence described by Anilionis et al. (4) , which codes for leucine at position 8 for a functional gene product, the cloned sequence was changed by site-directed mutagenesis to code for proline at position 8 and inserted into a second vaccinia vector derived from the Copenhagen vaccinia strain (23) . Both recombinant viruses (V-RGleu8 and V-RGpro8) produced a protein of similar size that was detected in fixed preparations of infected cells by immunofluorescence using monospecific antiserum raised against rabies virus G. However, the V-RGpro8 virus-expressed antigen, but not the V-RGleu8 antigen, was detectable at high density on the surface of infected cells and reacted with monoclonal antibodies recognizing native rabies virus G. This information indicates that the V-RGleu8 virus rabies G has an altered antigenic structure. Remarkably, a single amino acid substitution near the NH2 terminus evidently results in a generally altered conformation of G, which may affect either post-translational modification or In humans, rabies vaccination is used primarily for treatment after exposure to the virus. It has been postulated that not only VNA but also CTL responses are important in postexposure protection (34, 35) . Mice immunized with VRGpro8 virus generated a substantial secondary cytotoxic response in vitro after re-exposure of lymphocytes to PM or ERA rabies viruses (Fig. 3) or in vivo after inoculation of VRGpro8 virus-immunized mice with ERA rabies virus (unpublished data). The CTL generated were specific for rabies G and lysed target cells infected with V-RGpro8 or ERA rabies viruses. A similar priming effect also has been demonstrated after immunization with a vaccinia recombinant virus expressing the influenza virus hemagglutinin (36) .
Despite the ability of V-RGpro8 virus to induce CTL memory specific for rabies G, primary rabies-specific CTL responses were weak. Since V-RGpro8 did induce a primary vaccinia-specific CTL response, this finding may reflect some form of immunodominance; however, the mechanisms involved are unclear (37) .
Live vaccinia virus has a long history of safe use as a vaccine for humans, despite a low incidence of serious complications (38) . Reintroduction of vaccinia virus-based vaccines may be controversial; therefore, we have evaluated the immunogenicity of purified inactivated V-RGpro8 virus and the rabies G isolated from V-RGpro8 virus-infected cells. Both preparations induced rabies VNA and protected mice against rabies. Induction of VNA by inactivated V-RGpro8 virus implies that the rabies G is closely associated with the V-RGpro8 virion. Immunoelectron microscopy should clarify whether the rabies G is a component of the viral membrane. However, these initial results suggest the possibility that inactivated V-RGpro8 virus could also be used as a vaccine against rabies. This work was supported by Research Grants AI-09706 and Al-18883 from the National Institute of Allergy and Infectious Diseases.
